-
Innovation Ranking
NewInnovation Ranking – Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc (Vanda) a biopharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a typical antipsychotic for the treatment of schizophrenia in adults. Its major pipeline products include Tradipitant (VLY-686), VTR-297, VQW-765, CFTR and portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. Vanda is headquartered in Washington, Washington DC, the US.
-
Company Insights
Innovation and Patenting activity of Vanda Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vanda Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VSJ-110 in Allergic Conjunctivitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VSJ-110 in Allergic Conjunctivitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VSJ-110 in Allergic Conjunctivitis Drug Details: VSJ-110 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INV-1120 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INV-1120 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INV-1120 in Pancreatic Cancer Drug Details: INV-1120 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iloperidone in Bipolar I Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iloperidone in Bipolar I Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iloperidone in Bipolar I Disorder Drug Details: Iloperidone (Fanapt/ Fanaptum) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TTI-101 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TTI-101 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TTI-101 in Gastric Cancer Drug Details: TTI-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tasimelteon in Insomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tasimelteon in Insomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tasimelteon in Insomnia Drug Details: Tasimelteon (Hetlioz) is a derivative of benzofuran acts...
-
Sector Analysis
Insomnia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Insomnia Market Report Overview The Insomnia market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $3.2 billion in 2022. Steady growth is anticipated at a CAGR of more than 2% from 2022 to 2032, due to the launch of four novel pipeline agents - Hetlioz, SM-1, vornorexant, and sunobinop. The insomnia market research report offers an overview of insomnia, including its epidemiology, symptoms, diagnosis, and disease management. The report offers key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VHX-896 in Bipolar I Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VHX-896 in Bipolar I Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VHX-896 in Bipolar I Disorder Drug Details: VHX-896 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VHX-896 in Schizophrenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VHX-896 in Schizophrenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VHX-896 in Schizophrenia Drug Details: VHX-896 is under development for the treatment of...